A lab technician works in the P3, the Pasteur Institute's laboratory dedicated to the Ebola virus, in Bangui on May 31, 2018. Photo: FLORENT VERGNES/AFP/Getty Images.

Genetic sequencing has confirmed that the outbreak of the deadly Ebola virus in North Kivu, in the eastern part of the Democratic Republic of the Congo, is distinct from an earlier outbreak in the same country — the earlier outbreak was declared over in late July.

Why it matters: Public health officials are racing to contain the new outbreak in a challenging operational environment near the borders with Rwanda and Uganda, which is home to more than a million displaced people. This region is home to many rebel groups and hosts the largest U.N. peacekeeping contingent in the world.

Details: According to a tweet from Peter Salama, the World Health Organization's deputy director-general for emergency preparedness and response, health workers plan to begin vaccinating people in affected areas of North Kivu starting on Wednesday.

Doctors used the experimental vaccine, known as rVSV-ZEBOV, to treat those exposed to the virus during the last outbreak in the Congo.

The current outbreak's death toll has climbed.

The WHO has warned that security issues could present a significant impediment to addressing the outbreak.

  • "The prolonged humanitarian crisis and deterioration of the security situation is expected to hinder response to this outbreak," the WHO said.

What's next: Although Salama did not specify how the vaccine would be used, during the last outbreak the agency worked with other organizations to conduct a ring vaccination program. This involves vaccinating people who have come into direct contact with individuals confirmed to have Ebola — as well as the contacts of those contacts. Each ring might include about 150 people.

  • In addition, the WHO gave the vaccine to health care works to protect them while treating Ebola patients.

The vaccine is considered experimental because the largest testing occurred in Guinea at the end of the 2015 outbreak, and was not conducted in a way that would satisfy regulatory agencies like the Food and Drug Administration.

Go deeper: Experimental vaccine used to fight Congo's Ebola outbreak

Go deeper

Media prepares to fact check debates in real time

Illustration: Annelise Capossela/Axios

From live blogs to video chyrons and tweets, media companies are introducing new ways to fact check the presidential debates in real time this year.

Between the lines: The debates themselves are likely to leave less room for live fact-checking from moderators than a traditional news interview would.

Life after Roe v. Wade

The future seems clear to both parties: The Supreme Court will overturn Roe v. Wade in the next few years, either gradually or in one fell swoop, and the abortion wars will move to a state-by-state battle over freedom and restrictions. 

What's new: Two of the leading activists on opposite sides of the abortion debate outlined for “Axios on HBO” the next frontiers in a post-Roe v. Wade world as the balance on the Supreme Court prepares to shift.

Dion Rabouin, author of Markets
48 mins ago - Economy & Business

Jerome Powell, Trump's re-election MVP

Photo illustration: Annelise Capossela/Axios. Getty Images photos: Andrew Caballero-Reynolds/AFP and Lev Radin/Pacific Press/LightRocket

President Trump trails Joe Biden in most polls, has generally lower approval ratings and is behind in trust on most issues. Yet polls consistently give him an edge on the economy, which remains a top priority among voters.

Why it matters: If Trump wins re-election, it will largely be because Americans see him as the force rallying a still-strong U.S. economy, a narrative girded by skyrocketing stock prices and consistently climbing U.S. home values — but the man behind booming U.S. asset prices is really Federal Reserve chair Jerome Powell.